

DAFTAR PUSTAKA

- Addo, Marylyn M & Marcus Altfeld. 2014. "Sex-Based Differences in HIV Type 1 Pathogenesis." *The Journal of Infectious Diseases* 209 (Suppl 3). doi:10.1093/infdis/jiu175.
- Albrecht, Dirk, Marcus Altfeld, U Fritz Bredeek, Laura Dickinson, Hermione Lyall, & Leonie Meemken. 2006. *HIV Medicine 2006*. Cologne: Flying Publisher.
- Alomar, Muaed Jamal. 2014. "Factors Affecting the Development of Adverse Drug Reactions (Review Article)." *Saudi Pharmaceutical Journal* 22 (2). King Saud University: 83–94. doi:10.1016/j.jsps.2013.02.003.
- Angraini, Rika Dwi. 2014. "Hubungan Indeks Masa Tubuh (IMT), Aktivitas Fisik, Rokok, Konsumsi Buah, Sayur Dan Kejadian Hipertensi Pada Lansia Di Pulau Kalimantan (Analisis Data Riskesdas 2007)." Universitas Esa Unggul. [http://digilib.esaunggul.ac.id/public/UEU-Undergraduate-2408-SKRIPSI RIKA _201032009 \(GIZI UNIV ESA UNGGUL\).pdf](http://digilib.esaunggul.ac.id/public/UEU-Undergraduate-2408-SKRIPSI RIKA _201032009 (GIZI UNIV ESA UNGGUL).pdf). (diakses 26 Februari 2016)
- Ardern-jones, Michael R, & Peter S Friedmann. 2011. "Skin Manifestations of Drug Allergy." *British Journal of Clinical Pharmacology* 71 (5): 672–83. doi:10.1111/j.1365-2125.2010.03703.x.
- Arjana, Adhika Zhulhi. 2013. "Profil Ekspresi CD45RO Pada Sel T CD4 Penderita HIV Dan Hubungannya Dengan Jumlah Sel T CD4+ Serta Stadium Klinis." Universitas Gadjah Mada. <http://infolib.med.ugm/> (diakses 4 Juni 2015)
- Baldo, B., & N.H. Pham. 2013. "Classification and Descriptions of Allergic Reactions to Drugs." dalam *Drug Allergy: Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships*, 15–36. doi:10.1007/978-1-4614-7261-2.
- Barba, Corazon, Tommaso Cavalli-Sforza, Jeffery Cutter, Ian Darnton-Hill, & *et al.* 2004. "Public Health Appropriate Body-Mass Index for Asian Populations and Its Implications for Policy and Intervention Strategies." *The Lancet* 363: 157–63.
- Bersoff-matcha, Susan J, William C Miller, Judith A Aberg, Charles Van Der Horst, H James Hamrick, William G Powderly, & Linda M Mundy. 2001. "Sex Differences in Nevirapine Rash." *Clinical Infectious Diseases* 63141 (32): 124–29.
- Boehringer Ingelheim. 2005. "Viramune ® (Nevirapine) Tablets & Oral Suspension." Vol. 1. Ridgefield.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,20933s014lbl.pdf. (diakses 29 Maret 2016)

Brunton, Laurence L., John S. Lazo, & Keith L. Parker. 2006. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. The McGraw-Hill Companies, Inc.

Castle, Steven C. 2000. "Clinical Relevance of Age-Related Immune Dysfunction." *Clinical Infectious Diseases* 31: 578–85.

Castro, Cornejo E.M., Carr D.F., Jorgensen A.L., Alfirovic A, & Pirmohamed M. 2015. "HLA-Allelotype Associations with Nevirapine-Induced Hypersensitivity Reactions and Hepatotoxicity: A Systematic Review Of The Literature and Meta-Analysis." *Pharmacogenet Genomics* 24 (4): 186–98. doi:10.1097/FPC.0000000000000124.

CDC. n.d. "Body Mass Index : Considerations for Practitioners." <http://www.cdc.gov/obesity/downloads/bmiforpractitioners.pdf>. (diakses 26 Februari 2016)

Chandra, Ranjit Kumar. 1991. "1990 McCollum Award Lecture. Nutrition and Immunity: Lessons from the Past and New Insights into the Future." *Am J Clin Nutr* 53: 1087–1101.

Chaponda, Mas, & Munir Pirmohamed. 2010. "Hypersensitivity Reactions to HIV Therapy." *British Journal of Clinical Pharmacology* 71 (5): 659–71. doi:10.1111/j.1365-2125.2010.03784.x.

Dailly, Eric, Eric Billaud, Veronique Reliquet, Sebastien Breurec, Philippe Perre, Sophie Leautez, & *et al.* 2004. "No Relationship between High Nevirapine Plasma Concentration and Hepatotoxicity in HIV-1-Infected Patients Naive of Antiretroviral Treatment or Switched from Protease Inhibitors." *Eur J Clin Pharmacol* 60: 343–48. doi:10.1007/s00228-004-0769-5.

Demoly, Pascal, Marinella Viola, Eva Rebelo Gomes, & Antonino Romano. 2007. "Epidemiology and Causes of Drug Hypersensitivity." dalam *Drug Hypersensitivity*, edited by W.J. Pichler, 2–17. Basel: Karger.

Depkes. 2006. *Pedoman Pelayanan Kefarmasian Untuk Orang Dengan HIV/AIDS (ODHA)*. Jakarta: Departemen Kesehatan Republik Indonesia - Ditjen Bina Kefarmasian dan Alat Kesehatan.

Dhoro, Milcah, & Katrin Sangkuhl. 2016. "Nevirapine Pathway, Pharmacokinetics." <https://www.pharmgkb.org/pathway/PA165950411#tabview=tab0&subtab=>. (diakses 4 Desember 2016).

Dong, Betty J, Yu Zheng, Michael D Hughes, Adam Frymoyer, Patty Lizak, Frederick Sawe, Judith S Currier, & Shahin Lockman. 2012. "NIH Public

Access.” *AIDS* 26 (7): 833–41.

doi:10.1097/QAD.0b013e328351a521.Nevirapine.

Fauci, A.S., & H.C. Lane. 2012. “Human Immunodeficiency Virus Disease: AIDS and Related Disorders.” dalam *Harrison’s Principles of Internal Medicine 18th Edition*, edited by D.L. Longo, D.L. Kasper, J.L. Jameson, A.S. Fauci, S.L. Hauser, & Joseph Loscalzo. New York: McGraw Hill.

Franconi, Flavia, Sandra Brunelleschi, Luca Steardo, & Vincenzo Cuomo. 2007. “Gender Differences in Drug Responses.” *Pharmacological Research* 55: 81–95. doi:10.1016/j.phrs.2006.11.001.

Green, Bruce, & Stephen B Duffull. 2004. “What Is the Best Size Descriptor to Use for Pharmacokinetic Studies in the Obese?” *British Journal of Clinical Pharmacology* 58 (2): 119–33. doi:10.1111/j.1365-2125.2004.02157.x.

Grinspoon, Steven, & Kathleen Mulligan. 2003. “Weight Loss and Wasting in Patients Infected with Human Immunodeficiency Virus.” *Clinical Infectious Diseases* 2114 (Suppl 2): 69–78.

Hall, Ronald G, Mark A Swancutt, & Tawanda Gumbo. 2011. “Fractal Geometry and the Pharmacometrics of Micafungin in Overweight , Obese , and Extremely Obese People.” *Antimicrobial Agents and Chemotherapy* 55 (11): 5107–12. doi:10.1128/AAC.05193-11.

Harris, M, Zala C, Hogg R, & Montaner JSG. 2008. “Nevirapine.” dalam *AIDS Therapy*, edited by Raphael Dolin M, Henry Masur M, & Michael Saag M, 3rded., 233–45. Philadelphia: Elsevier Inc.

Hendrik. 2011. “Hubungan Indeks Massa Tubuh Dengan Tekanan Darah Pada Mahasiswa Fakultas Kedokteran Universitas Sumatera Utara.” Universitas Sumatera Utara. <http://repository.usu.ac.id/handle/123456789/31021>. (diakses 4 Mei 2016).

Hu, Teh-min, & William L Hayton. 2001. “Allometric Scaling of Xenobiotic Clearance : Uncertainty versus Universality.” *AAPS PharmSci* 3 (4). <http://www.pharmsci.org/>.

Katzung, Bertram G., Susan B. Masters, & Anthony J. Trevor. 2012. *Basic & Clinical Pharmacology*. 12thed. The McGraw- Hill Companies, Inc.

Kemenkes. 2011. *Pedoman Nasional Tatalaksana Klinis Infeksi HIV Dan Terapi Antiretroviral*. Kementerian Kesehatan RI- Ditjen Pengendalian Penyakit dan Penyehatan Lingkungan.

Kemenkes. 2014. *Infodatin: Situasi Dan Analisis HIV AIDS.pdf*. Jakarta: Kementerian Kesehatan RI- Pusat Data dan Informasi.

- Kiertiburanakul, Sasisopin, Somnuek Sungkanuparph, Kumthorn Malathum, Siriorn Watcharananan, Boonmee Sathapatayavongs, & *et al.* 2009. "A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-Infected Patients : In Settings of Low CD4 Cell Counts and Resource." *The Open AIDS Journal* 3: 24–30.
- Kleiber, Max. 1932. "Body Size and Metabolism." *Hilgardia* 6 (11).
- Maat, Monique M R De, Rob ter Heine, Jan W Mulder, Pieter L Meenhorst, Albert Mairuhu, Alwin D R Huitema, & Jos H Beijnen. 2003. "Incidence and Risk Factors for Nevirapine-Associated Rash." *Eur J Clin Pharmacol* 59: 457–62. doi:10.1007/s00228-003-0613-3.
- Maat, Monique M R De, Alwin D R Huitema, Jan W Mulder, Pieter L Meenhorst, Eric C M Van Gorp, & Jos H Beijnen. 2002. "Population Pharmacokinetics of Nevirapine in an Unselected Cohort of HIV-1-Infected Individuals," 378–85.
- Marinho, Aline T, M Rodrigues, Umbelina Caixas, Alexandra M M Antunes, Teresa Branco, C Monteiro, & Sofia A Pereira. 2014. "Differences in Nevirapine Biotransformation as a Factor for Its Sex-Dependent Dimorphic Profile of Adverse Drug Reactions." *Journal Antimicrobial Chemotherapy* 69: 476–82. doi:10.1093/jac/dkt359.
- Milpied-Homsi, Brigitte, Ellen M. Moran, & Elizabeth J. Philips. 2015. "Antiviral Drug Allergy." *Immunol Allergy Clin North Am.* 2014 34 (3): 645–62. doi:10.1016/j.iac.2014.04.011.
- mims.com. 2016. "Nevirapine." Accessed December 4. <http://mims.com/indonesia/drug/info/nevirapine/?type=brief&mtype=generic>. (diakses 4 Desember 2016).
- National Obesity Observatory. 2009. "Body Mass Index as a Measure of Obesity," no. (diakses 25 Februari 2016). http://www.noo.org.uk/uploads/doc789_40_noo_BMI.pdf.
- Ofotokun, Ighovwerha, & Claire Pomeroy. 2003. "Sex Differences in Adverse Reactions to Antiretroviral." Vol. 11. Topics in HIV Medicine.
- Osborne, N.J., Ben Amos, & Jessica Tyrrell. 2014. "Adult Drug and Food Allergy in the UK Biobank Cohort Study." *International Science Environmental Epidemiology Conference 2014*. <http://ehp.niehs.nih.gov/isee/p3-565/>. (diakses 10 Februari 2016)
- Permata, Adinda. 2011. "Perbedaan Kadar Glukosa Darah Pada Anak Dengan Indeks Massa Tubuh Normal Dan Overweight." Universitas Muhammadiyah Surakarta. <http://eprints.ums.ac.id/14856/>. (diakses 4 Mei 2016)

- Peter, J.G., J.P. Mouton, & R. Lehloenya. 2015. "Immune-Mediated Adverse Drug Reactions in South Africa." *Current Allergy & Clinical Immunology* 28 (3).
- Pichler, W, N Yawalkar, S Schmid, & A Helbling. 2002. "Pathogenesis of Drug-Induced Exanthems." *Allergy* 57: 884–93.
- Pichler, Werner J. 2007. "Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation." dalam *Drug Hypersensitivity*, edited by W.J. Pichler, 168–89. Bern: Karger.
- Pirmohamed, M. 2007. "HIV and Drug Hypersensitivity." dalam *Drug Hypersensitivity*, edited by W.J. Pichler, 84–94. Bern: Karger.
- Riggs, Amy Jo, Barry D White, & Sareen S Gropper. 2007. "Changes in Energy Expenditure Associated with Ingestion of High Protein , High Fat versus High Protein , Low Fat Meals among Underweight , Normal Weight , and Overweight Females." *Nutrition Journal* 6 (40). doi:10.1186/1475-2891-6-40.
- Ring, Johannes. 2005. *Allergy in Practice*. Springer - Verlag Berlin Hiedelberg New York.
- Sanne, Ian, Herve Mommeja-marin, John Hinkle, John A Bartlett, Michael M Lederman, Gary Maartens, Charles Wakeford, et al. 2005. "Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects." *The Journal of Infectious Diseases* 191: 825–29.
- Sastroasmoro, S. & Ismael, S., 2011. *Dasar-Dasar Metodologi Penelitian Klinis* 4th ed., Jakarta: CV Agung Seto.
- Schipani, Alessandro, Christoph Wyen, Tabitha Mahungu, Heidy Hendra, Deirdre Egan, Marco Siccardi, Michael Youle, & et al. 2011. "Integration of Population Pharmacokinetics and Pharmacogenetics : An Aid to Optimal Nevirapine Dose Selection in HIV-Infected Individuals," *Journal Antimicrobial Chemotherapy* , 2–9. doi:10.1093/jac/dkr087.
- Schnyder, Benno, & Werner J. Pichler. 2009. "Mechanisms of Drug-Induced Allergy." In *Mayo Clin Proc.*, 84:268–72.
- Sehgal, Virender N., & Om P. Gangwani. 1987. "Fixed Drug Eruption: Current Concepts." *International Journal of Dermatology* 26 (2): 67–75.
- Shenton, J M, M Popovic, & J P Uetrecht. 2007. "Nevirapine Hypersensitivity." dalam *DrugHypersensitivity*, edited by W.J. Pichler, 115–21. Basel: Karger.
- Shubber, Zara, A. Calmy, I. Andrieux-Meyer, M.Vitoria, F. Renaud-Théry, N. Shaffer, S. Hargreaves, & E.J. Mills N. Ford. 2013. "Adverse Events

Associated with Nevirapine and Efavirenz-Based First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis.” *AIDS* 27 (9): 1403–12. doi:10.1097/QAD.0b013e32835f1db0.

Tansuphaswadikul, Somsit, Saw Eindani Aung, Benjaluck Phonrat, Jaranit Kaewkungwal, Punnee Pitisuttithum, & Wirach Maek-a-nantawat. 2007. “Predisposing Factors for Nevirapine Toxicity among AIDS Patients with Low Baseline CD4 Count.” *Asian Pacific Journal of Allergy and Immunology* 25 (2–3): 147–54.

Thong, Bernard, & Daniel Vervloet. 2014. “Drug Allergies.” http://www.worldallergy.org/professional/allergic_diseases_center/drugallergy/. (diakses 1 April 2016)

Warrington, Richard, & Fanny Silviu-dan. 2011. “Immunology Drug Allergy.” *Allergy, Asthma, & Clinical Immunology* 7 (Suppl 1): 1–8.

WHO. 2005. “Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance- African Region.” <http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf>.

Wit, Ferdinand W N M, Anouk M Kesselring, Luuk Gras, Clemens Richter, Marchina E Van Der Ende, Kees Brinkman, & *et al.* 2008. “Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience , Compared with Treatment- Naive Patients : The ATHENA Cohort Study.” *Clinical Infectious Diseases* 46: 933–40. doi:10.1086/528861.

Yayasan Spiritia. 2014. “Lembaran Informasi 106--Siklus Hidup HIV.” <http://spiritia.or.id/li/pdf/LI106.pdf>. (diakses 2 April 2016)